<sup>90</sup>Y-DOTATOC Dosimetry–Based Personalized Peptide Receptor Radionuclide Therapy
Yusuf Menda(University of Iowa), M. Sue O’Dorisio(The Ohio State University), David Bushnell(Cytel (United States)), Michael K. Schultz(University of Iowa), Gideon Zamba(University of Iowa), Sarah L. Mott(University of Iowa), John J. Sunderland(University of Iowa), Mark T. Madsen(University of Iowa), Joseph S. Dillon(University of Iowa), G. Leonard Watkins(University of Iowa), Thomas M. O’Dorisio(University of Iowa)
Cited by 51
Related Papers
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Aberrant CpG-island methylation has non-random and tumour-type–specific patterns
|Nature Genetics|2000|1.4k
Health-Related Quality of Life in Patients With Progressive Midgut Neuroendocrine Tumors Treated With <sup>177</sup>Lu-Dotatate in the Phase III NETTER-1 Trial
|Journal of Clinical Oncology|2018|388
Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs.
|PubMed|2005|375
Sarcopenia is an independent predictor of complications following pancreatectomy for adenocarcinoma
|Journal of Surgical Oncology|2014|274